Icahn School of Medicine at Mount Sinai

Icahn School of Medicine at Mount Sinai Excellence in research, education and patient care are hallmarks of our educational philosophy. Our students are tomorrow's leaders. News & World Report.
(448)

To contact the admissions office, please email admissions@mssm.edu As one of the nation’s leading medical schools, Icahn School of Medicine at Mount Sinai ranks 18th out of 126 medical schools nationwide, according to U.S. We have built our reputation on a tradition of excellence inspired by visionary leaders, esteemed faculty, and outstanding trainees. Our progressive curriculum stresses a compas

sionate and collaborative approach to medical practice and scientific investigation. Find out more about the educational opportunities available to you as a student at Icahn School of Medicine at Mount Sinai. Learn more at http://icahn.mssm.edu

04/20/2026

Congratulations to Andrew B. Leibowitz, MD, MSSM '83, MSH '89, on receiving the 2026 Jacobi Medallion Award.

Dr. Leibowitz is a nationally recognized leader in anesthesiology and critical care medicine. He played a key role in developing the Central Venous Access Service, which evolved into the current Vascular Access Service. He was among the first in the non-operating room setting to routinely incorporate ultrasound and fluoroscopy for central line and PICC placement, that enabled the routine early discharge of patients requiring long-term intravenous therapies

Appointed Chair in 2014, Dr. Leibowitz led the integration of anesthesiology services across multiple hospitals, marking the System’s first fully unified service-line merger. Under his leadership, the department further expanded and now houses the country’s largest anesthesiology training program with more than 2% of the nation’s house staff, and performs more than 120,000 anesthetics per year.

A landmark review from the Icahn School of Medicine at Mount Sinai, published in Cell, offers one of the clearest roadma...
04/18/2026

A landmark review from the Icahn School of Medicine at Mount Sinai, published in Cell, offers one of the clearest roadmaps to date for understanding and treating liver cancer—one of the deadliest cancers worldwide.

Led by Josep M. Llovet, MD, PhD, and Daniela Sia, PhD, the study applies the influential “Hallmarks of Cancer” framework to liver tumors, linking key biological drivers of disease to emerging treatment strategies, including immunotherapy and precision medicine. The work highlights how different forms of liver cancer develop and identifies critical vulnerabilities—particularly in bile duct cancers, where nearly half of tumors harbor targetable genetic alterations.

By bridging decades of research with clinical application, this review provides a powerful framework to guide more personalized treatment approaches and accelerate the development of new therapies for patients.

04/17/2026

Please join us in congratulating Claudia I. Henschke, PhD, MD, on being a 2026 Jacobi Medallion Recipient.

Dr. Henschke is a pioneer in diagnostic radiology whose work has transformed the early detection of lung cancer and demonstrated that women are at greater risk than men. She has long believed that individuals who smoke (or those exposed to smoke) should be screened to detect early lung cancer, when a tumor is still small enough to be cured.

She is the founder and head of the International Early Lung Cancer Action Program (I-ELCAP), a global collaboration of physicians and scientists who are experts on lung cancer-related issues. Their work has supported continued improvement of the lung screening process, which has led early on to comprehensive screening.

This coming Monday, the Icahn School of Medicine community comes together for Mount Sinai's .Join us for a day focused ...
04/16/2026

This coming Monday, the Icahn School of Medicine community comes together for Mount Sinai's .

Join us for a day focused on awareness, early detection, and community support. From educational sessions to on-site screenings and donor registration, you can be part of something that truly saves lives.

Students can take action by joining the registry on-site with NMDP. Blood stem cell donation gives patients battling blood cancer a second chance—and the process is more accessible than many think.

The Mount Sinai Hospital
Guggenheim Pavilion Lobby
9:00 AM – 3:00 PM

Researchers at the Icahn School of Medicine at Mount Sinai have identified the most common recessive neurodevelopmental ...
04/15/2026

Researchers at the Icahn School of Medicine at Mount Sinai have identified the most common recessive neurodevelopmental disorder discovered to date—offering long-awaited answers for families and new direction for future therapies.

Published in Nature Genetics, the study reveals that changes in the RNU2-2 gene lead to a condition now known as recessive ReNU2 syndrome, estimated to account for a significant portion of previously unexplained cases. The disorder is caused by a near absence of U2-2 RNA, disrupting typical brain development and leading to a wide range of symptoms, from developmental delays and limited speech to epilepsy and movement disorders.

By uncovering the genetic and molecular basis of this condition, researchers are not only improving diagnostic clarity for families, but also identifying a potential path toward gene replacement strategies in the future.

Read more: https://mshs.co/41BUEAj

New research from the Icahn School of Medicine at Mount Sinai reveals a potential new way that SARS-CoV-2 spreads within...
04/15/2026

New research from the Icahn School of Medicine at Mount Sinai reveals a potential new way that SARS-CoV-2 spreads within the body—by turning previously resistant cells into targets for infection.

Published in Nature Communications, the study shows that lung cells release tiny particles, known as extracellular vesicles, that carry key viral entry proteins. When taken up by other cells—including immune and blood vessel cells—these vesicles can make them newly susceptible to infection.

This mechanism may help explain how COVID-19 affects multiple organ systems and contributes to severe complications like inflammation, clotting, and organ damage. The findings also point to a potential therapeutic strategy: blocking this protein transfer to limit viral spread within the body.

Are you looking for a biomedical science program that aligns with your career goals?At the Icahn School of Medicine, our...
04/15/2026

Are you looking for a biomedical science program that aligns with your career goals?

At the Icahn School of Medicine, our Master of Science in Biomedical Science (MSBS) program offers four tracks for students to chose from. These tracks enable our students to pursue their career goals upon completing the program, whether they want to apply for a PhD, medical school, or gain skills to enhance their current position. Hear from Program Director Jose Silva about these tracks and why: https://mshs.co/4vikkPY

04/13/2026

Congratulations to John Cijiang He, MD, PhD, MSH '03, on being a 2026 Jacobi Medallion Recipient.

Dr. He is an internationally recognized physician-scientist whose work has significantly advanced the understanding of glomerular biology, diabetic kidney disease, HIV-associated nephropathy, and kidney fibrosis. His research has led to multiple patents and translational therapeutic strategies targeting kidney disease.

As a clinical and administrative leader, Dr. He has played a central role in expanding nephrology services across the Mount Sinai Health System. Under his leadership, the division has grown to include more than 60 faculty, manages over 1,000 dialysis patients across 18 dialysis centers, operates one of the largest home dialys is programs in the country, and maintains a chronic kidney disease registry exceeding 160,000 patients.

A new study published in Radiology highlights a growing challenge at the intersection of artificial intelligence and cli...
04/11/2026

A new study published in Radiology highlights a growing challenge at the intersection of artificial intelligence and clinical care: the ability to distinguish real medical images from AI-generated “deepfakes.” Led by Mickael Tordjman, MD, researchers at Mount Sinai found that both radiologists and advanced multimodal AI models struggle to reliably identify synthetic X-rays—even when they are aware such images are present.

The findings raise important concerns around diagnostic accuracy, cybersecurity, and the integrity of medical records, pointing to the urgent need for safeguards such as image authentication tools, watermarking, and clinician training. As synthetic imaging technologies rapidly evolve, this research underscores the importance of preparing health care systems to detect and defend against potential misuse.

Researchers at Mount Sinai are advancing pediatric rehabilitation through the integration of motion capture technology a...
04/10/2026

Researchers at Mount Sinai are advancing pediatric rehabilitation through the integration of motion capture technology and neurostimulation therapies. Led by David F. Putrino, PhD, the Charles Lazarus Children’s Abilities Center is developing a marker-based, multi-camera motion capture facility that will enable clinicians to objectively evaluate how neurostimulation treatments affect movement in children with chronic neurological disabilities.

The facility—one of only two of its kind in New York City—will allow researchers to conduct safety and feasibility studies assessing whether these technologies can restore neurotypical movement patterns in pediatric patients. By combining advanced motion analysis with rehabilitation therapies, Mount Sinai investigators hope to generate critical evidence to guide the use of emerging neurostimulation treatments and expand options for children living with neurological impairment.

Read more in the Specialty Report: https://mshs.co/4sIZ6Zl

Researchers at the Icahn School of Medicine at Mount Sinai have identified a molecular “brake” that limits the ability o...
04/10/2026

Researchers at the Icahn School of Medicine at Mount Sinai have identified a molecular “brake” that limits the ability of neurons to repair after injury—offering a promising new direction for treating nerve and spinal cord damage.

Published in Nature, the study shows that a protein called the aryl hydrocarbon receptor (AHR) restricts axonal regeneration by shifting neurons toward stress response rather than repair. When researchers blocked AHR, damaged nerve fibers regrew more effectively and recovery of motor and sensory function improved in preclinical models.

These findings provide new insight into how neurons balance survival and regeneration—and suggest that targeting AHR could help unlock the nervous system’s ability to heal.

We were proud to celebrate the 2026 Jacobi Medallion recipients, honoring individuals for their distinguished contributi...
04/08/2026

We were proud to celebrate the 2026 Jacobi Medallion recipients, honoring individuals for their distinguished contributions to the field of medicine or extraordinary service to the Hospital, Health System, School of Medicine, or alumni community.

Thank you to the friends, families, and colleagues who joined us in recognizing these exceptional leaders and their enduring legacy at the 2026 Jacobi Medallion Ceremony.

Congratulations to our 2026 Recipients:
John Cijiang He, MD, PhD, MSH '03
Claudia I. Henschke, PhD, MD
Andrew B. Leibowitz, MD, MSSM '83, MSH '89
Marek Mlodzik, PhD
Meg A. Rosenblatt, MD, MSH '89
Kenneth E. Rosenzweig, MD
Mone Zaidi, MD, PhD

Address

1468 Madison Avenue
New York, NY
10029

Website

Alerts

Be the first to know and let us send you an email when Icahn School of Medicine at Mount Sinai posts news and promotions. Your email address will not be used for any other purpose, and you can unsubscribe at any time.

Contact The Practice

Send a message to Icahn School of Medicine at Mount Sinai:

Shortcuts

Featured

Share

Category